M S Kramer
Affiliation: Merck Research Laboratories
- Distinct mechanism for antidepressant activity by blockade of central substance P receptorsM S Kramer
Merck Research Laboratories, West Point, PA 19456, USA
Science 281:1640-5. 1998..These findings suggest that substance P may play an important role in psychiatric disorders...
- Improvement in migraine-specific quality of life in a clinical trial of rizatriptanN C Santanello
Merck and Co, Inc, West Point, PA 19486, USA
Cephalalgia 17:867-72; discussion 800. 1997..The O'Brien's Rank Sum Test statistic showed a statistically significant overall difference on the 24-h MQoLQ between the 10 mg rizatriptan and placebo groups (p=0.005) and for the overall dose trend (p< or =0.001)...
- Novel strategies for pharmacotherapy of depressionK A Maubach
Merck Sharp and Dohme Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK
Curr Opin Chem Biol 3:481-8. 1999..Efforts in this area have recently been rewarded by the demonstration of antidepressant efficacy of the substance P receptor antagonist MK-0869...
- Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonistsN M Rupniak
Merck Sharp and Dohme Neuroscience Research Centre, Harlow, Essex, UK
Trends Pharmacol Sci 20:485-90. 1999..Thus, multiple clinical trials, targeted to appropriate patient populations, are necessary to define the therapeutic potential of novel neurotransmitter ligands...